Syngene’s acquisition of its first US manufacturing facility not due to geopolitical tensions

URLhttps://www.pharmamanufacturing.com/all-articles/a
SourcePharma Manufacturing
Date Published06/02/2025
Author NameGreg Slabodkin

Additional Reshoring Information:

Company/Division name Syngene
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):100
Year reshoring announced:2025
Year reshoring implemented or to be implemented:2025
Domestically, the work will be done:In-house
Capital investment ($):36.5
Country(ies) from which reshored:India
City reshored to:Baltimore
State(s) reshored to:MD
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharma (CRDMOs)
What non-domestic negative factors made offshoring less attractive?Supply chain interruption
What domestic positive factors made reshoring more attractive?Under-utilized capacity
Find Reshoring Articles